FRM
KERX

Fox Run Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Fox Run Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-14,200
Closed -$101K – 991
2017
Q3 		$101K Buy
+14,200
New +$102K 0.03% 641
2017
Q1 		– Sell
-10,600
Closed -$62K – 833
2016
Q4 		$62K Buy
+10,600
New +$57.9K 0.03% 478
2016
Q1 		– Sell
-20,000
Closed -$101K – 617
2015
Q4 		$101K Buy
+20,000
New +$95K 0.08% 360

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fox Run Management's KERX Position: Q4 2017 in Review

Fox Run Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 14,200 shares — an estimated $101K sold.

Fox Run Management first reported a position in KERX in Q4 2015 and held it in 3 quarters. The position peaked at $101K in Q3 2017. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Fox Run Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Fox Run Management sold 14,200 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $101K.
  • Fox Run Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 3 quarters.
  • Fox Run Management's Keryx Biopharmaceuticals Inc position peaked at $101K in Q3 2017.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Fox Run Management's 13F filing for Q4 2017, filed 18 Jan 2018.